What's next in Neuro?
Replay our Webinar
High-Throughput, Fully Automated Immunoassay for Detecting Zygosity of Apolipoprotein ε4 (APOEε4) in Plasma EDTA.
Download our Whitepaper
The Role of APOE in Alzheimer's Disease:
Genetic Variants, Mechanisms, and Therapeutic Implications.
Download and Share the NeuroABC Value Exploration
See how you can benefit from a collaboration with Beckman Coulter on RUO assay development.
Get Beckman Coulter Neurodegenerative items of interest delivered to your inbox.
To increase accessibility for Alzheimer's disease and neurodegenerative disease research, there is a need to bring research capabilities in house to reduce turn around time and outsourcing. ACCESS the right partner to position your lab for future success.
Learn More
Effective technology transfer is essential to move novel assays from research into clinical labs. Running clinical trials on the same platform intended for future in vitro diagnostic (IVD) testing gives you ACCESS to a strategic advantage by aligning research with scalable diagnostic implementation.
Learn More
Blood-based Neurodegenerative Disease Assays (RUO)
| BD-pTau 217 | IFU | DOWNLOAD PDF |
| p-Tau217 | IFU | DOWNLOAD PDF |
| GFAP | IFU | DOWNLOAD PDF |
| NfL | IFU | DOWNLOAD PDF |
| APOE ε4 | IFU | DOWNLOAD PDF |
| β-Amyloid 1-42 | IFU | DOWNLOAD PDF |
| BD-Tau | IFU | DOWNLOAD PDF |
Research Use Only Assays in Development
| MTBR-Tau (CSF-based) |
| TDP-43 |
| p‑Tau 205 |
Assay has been granted Breakthrough Device Designation (BDD) from the U.S. FDA
| p-Tau217/ß-AmyIoid 1-42 Plasma Ratio* |